ARHGEF2 and prostate carcinoma: In 75 out of 266 prostate cancer patients with overall survival of the first-line AR-targeted inhibitors treatment in the Abida-Wassim study25, higher expression of ARHGEF2 (p = 0.041), LHX2 (p = 0.0091), and EPHB2 (p = 0.15) showed correlation with shortened overall survival time (Fig. 5b), while DPYSL3, EPHB2, FYN, and GNG4 did not positively correlate with shortened overall survival.